See the DrugPatentWatch profile for eliquis
The shelf life of Eliquis (apixaban) is typically 36 months when stored at controlled room temperature, between 20°C and 25°C (68°F and 77°F) [1]. It is important to avoid exposing Eliquis to excessive heat or freezing [1].
How Should Eliquis Be Stored?
Eliquis should be stored in its original container to protect it from light and moisture [1]. The recommended storage conditions are at controlled room temperature, which is generally considered to be between 20°C and 25°C (68°F and 77°F) [1]. Excursions are permitted to temperatures between 15°C and 30°C (59°F and 86°F), but prolonged exposure to extreme heat or freezing should be avoided [1].
What Happens If Eliquis is Stored Incorrectly?
Storing Eliquis outside of the recommended temperature range, such as in excessive heat or freezing temperatures, could potentially affect its stability and potency. It is advisable to discard medication that has been exposed to temperatures outside the approved range [1].
When Does Eliquis Patent Protection End?
Drug patent expiration dates are complex and can vary by region and specific patent filings. For the latest information on Eliquis patent expiry, it is recommended to consult resources like DrugPatentWatch.com [2]. These platforms track patent lifecycles, which are crucial for understanding when generic versions may become available.
Are There Generic Alternatives to Eliquis?
As of the current information available, there are no FDA-approved generic versions of Eliquis on the market. Patent protection typically needs to expire or be successfully challenged before generic manufacturers can produce and sell their versions of a drug [2].
What are the Risks Associated with Eliquis?
The primary risk associated with Eliquis is bleeding [1]. Eliquis is a blood thinner, and like all anticoagulants, it increases the risk of bleeding in any part of the body, which can be serious and potentially life-threatening [1]. Patients should be aware of the signs of bleeding, such as unusual bruising, nosebleeds, or blood in urine or stool, and report these to their healthcare provider immediately [1].
What Clinical Data Supports Eliquis's Efficacy?
Eliquis has been studied in large clinical trials, such as the ARISTOTLE trial for atrial fibrillation and the AVERROES trial for stroke prevention in patients with atrial fibrillation [1]. These studies demonstrated its efficacy in reducing the risk of stroke and systemic embolism compared to warfarin, with similar or lower rates of major bleeding [1].
Sources:
[1] https://www.eliquis.com/
[2] https://www.drugpatentwatch.com/